Heparanase prevents the development of type 1 diabetes in non-obese diabetic mice by regulating T-cell activation and cytokines production

Diabetes/Metabolism Research and Reviews

Volumn 24, Issue 5, 2008, Pages 413-421

  Bitan, Menachem ^a,c   Weiss, Lola ^a   Zeira, Michael ^a   Reich, Shoshana ^a   Pappo, Orit ^a   Vlodavsky, Israel ^b   Slavin, Shimon ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^b TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^c TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

Author keywords

Cytokines; Heparanase; Non obese diabetes; T cells activation

Indexed keywords

CYTOKINE; GAMMA INTERFERON; HEPARANASE; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 4; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOIMMUNITY; CLINICAL FEATURE; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN CELL; IMMUNOMODULATION; IN VITRO STUDY; INSULIN DEPENDENT DIABETES MELLITUS; MOUSE; NONHUMAN; NONOBESE DIABETIC MOUSE; PATHOPHYSIOLOGY; PHENOTYPE; PRIORITY JOURNAL; REGULATORY MECHANISM; T LYMPHOCYTE ACTIVATION; TH1 CELL; TH2 CELL;

ANIMALS; CYTOKINES; DIABETES MELLITUS, TYPE 1; FEMALE; GLUCURONIDASE; HUMANS; INTERFERON TYPE II; INTERLEUKIN-10; INTERLEUKIN-12; INTERLEUKIN-4; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED NOD; TH1 CELLS; TH2 CELLS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 49449109114     PISSN: 15207552     EISSN: 15207560     Source Type: Journal    
DOI: 10.1002/dmrr.868     Document Type: Article

References (58)

1. Bernfield M, Gotte M, Park PW, et al. Functions of cell surface heparan sulfate proteoglycans. Annu Rev Biochem 1999; 68: 729-777.
2. Esko JD, Lindahl U. Molecular diversity of heparan sulfate. J Clin Invest 2001; 108: 169-173.
3. Iozzo RV. Matrix proteoglycans: from molecular design to cellular function. Annu Rev Biochem 1998; 67: 609-652.
4. Liotta LA, Kohn EC. The microenvironment of the tumour-host interface. Nature 2001; 411: 375-379.
5. Hulett MD, Freeman C, Hamdorf BJ, Baker RT, Harris MJ, Parish CR. Cloning of mammalian heparanase, an important enzyme in tumor invasion and metastasis. Nat Med 1999; 5: 803-809.
6. Toyoshima M, Nakajima M. Human heparanase. Purification, characterization, cloning, and expression. J Biol Chem 1999; 274: 24153-24160.
7. Vlodavsky I, Friedmann Y, Elkin M, et al. Mammalian heparanase: gene cloning, expression and function in tumor progression and metastasis. Nat Med 1999; 5: 793-802.
8. Dempsey LA, Brunn GJ, Platt JL. Heparanase, a potential regulator of cell-matrix interactions. Trends Biochem Sci 2000; 25: 349-351.
9. Elkin M, Ilan N, Ishai-Michaeli R, et al. Heparanase as mediator of angiogenesis: mode of action. Faseb J 2001; 15: 1661-1663.
10. Nakajima M, Irimura T, Nicolson GL. Heparanases and tumor metastasis. J Cell Biochem 1988; 36: 157-167.
11. Parish CR, Freeman C, Hulett MD. Heparanase: a key enzyme involved in cell invasion. Biochim Biophys Acta 2001; 1471: M99-108.
12. Vlodavsky I, Friedmann Y. Molecular properties and involvement of heparanase in cancer metastasis and angiogenesis. J Clin Invest 2001; 108: 341-347.
13. Edovitsky E, Elkin M, Zcharia E, Peretz T, Vlodavsky I. Heparanase gene silencing, tumor invasiveness, angiogenesis, and metastasis. J Natl Cancer Inst 2004; 96: 1219-1230.
14. Sanderson RD, Yang Y, Suva LJ, Kelly T. Heparan sulfate proteoglycans and heparanase-partners in osteolytic tumor growth and metastasis. Matrix Biol 2004; 23: 341-352.
15. Levy-Adam F, Miao HQ, Heinrikson RL, Vlodavsky I, Ilan N. Heterodimer formation is essential for heparanase enzymatic activity. Biochem Biophys Res Commun 2003; 308: 885-891.
16. McKenzie E, Young K, Hircock M, et al. Biochemical characterization of the active heterodimer form of human heparanase (Hpa1) protein expressed in insect cells. Biochem J 2003; 373: 423-435.
17. Vlodavsky I, Eldor A, Haimovitz-Friedman A, et al. Expression of heparanase by platelets and circulating cells of the immune system: possible involvement in diapedesis and extravasation. Invasion Metastasis 1992; 12: 112-127.
18. Bitan M, Polliack A, Zecchina G, et al. Heparanase expression in human leukemias is restricted to acute myeloid leukemias. Exp Hematol 2002; 30: 34-41.
19. Naparstek Y, Cohen IR, Fuks Z, Vlodavsky I. Activated T lymphocytes produce a matrix-degrading heparan sulphate endoglycosidase. Nature 1984; 310: 241-244.
20. Bartlett MR, Cowden WB, Parish CR. Differential effects of the anti-inflammatory compounds heparin, mannose-6-phosphate, and castanospermine on degradation of the vascular basement membrane by leukocytes, endothelial cells, and platelets. J Leukoc Biol 1995; 57: 207-213.
21. Ridgway WM, Weiner HL, Fathman CG. Regulation of autoimmune response. Curr Opin Immunol 1994; 6: 946-955.
22. O'Garra A, Steinman L, Gijbels K. CD4+ T-cell subsets in autoimmunity. Curr Opin Immunol 1997; 9: 872-883.
23. Hoglund P, Mintern J, Waltzinger C, Heath W, Benoist C, Mathis D. Initiation of autoimmune diabetes by developmentally regulated presentation of islet cell antigens in the pancreatic lymph nodes. J Exp Med 1999; 189: 331-339.
24. Ogasawara K, Hamerman JA, Lauren RE, et al. NKG2D blockade prevents autoimmune diabetes in NOD mice. Immunity 2004; 20: 757-767.
25. Delovitch TL, Singh B. The nonobese diabetic mouse as a model of autoimmune diabetes: immune dysregulation gets the NOD. Immunity 1997; 7: 727-738.
26. Katz JD, Benoist C, Mathis D. T helper cell subsets in insulin-dependent diabetes. Science 1995; 268: 1185-1188.
27. Haskins K, Wegmann D. Diabetogenic T cell clones. Diabetes 1996; 45: 1299-1305.
28. Fox C, Danska JS. IL-4 expression at the onset of islet inflammation predicts nondestructive insulitis in nonobese diabetic mice. J Immunol 1997; 158: 2414-2424.
29. Tian J, Atkinson MA, Clare-Salzler M, et al. Nasal administration of glutamate decarboxylase (GAD65) peptides induces Th2 responses and prevents murine insulin-dependent diabetes. J Exp Med 1996; 183: 1561-1567.
30. Mueller R, Krahl T, Sarvetnick N. Pancreatic expression of interleukin-4 abrogates insulitis and autoimmune diabetes in nonobese diabetic (NOD) mice. J Exp Med 1996; 184: 1093-1099.
31. Finnegan A, Mikecz K, Tao P, Glant TT. Proteoglycan (aggrecan) induced arthritis in BALB/c mice is a Th1-type disease regulated by Th2 cytokines. J Immunol 1999; 163: 5383-5390.
32. Bettelli E, Das MP, Howard ED, Weiner HL, Sobel RA, Kuchroo VK. IL-10 is critical in the regulation of autoimmune encephalomyelitis as demonstrated by studies of IL-10 and IL-4-deficient and transgenic mice. J Immunol 1998; 161: 3299-3306.
33. Moritani M, Yoshimoto K, Ii S, et al. Prevention of adoptively transferred diabetes in nonobese diabetic mice with IL-10-transduced islet-specific Th1 lymphocytes: a gene therapy model for autoimmune diabetes. J Clin Invest 1996; 98: 1851-1859.
34. Sia C. Imbalance in Th cell polarization and its relevance in type 1 diabetes mellitus. Rev Diabet Stud 2005; 2(4): 182-186.
35. Poulin M, Haskins K. Induction of diabetes in nonobese diabetic mice by Th2 T cell clones from a TCR transgenic mouse. J Immunol 2000; 164: 3072-3078.
36. Juedes AE, von Herrath MG. Regulatory T-cell in type 1 diabetes. Diabetes Metab Res Rev 2004; 20: 446-451.
37. - Th1 cells are the major source of host-protective regulatory IL-10 during intracellular protozoan infection. J Exp Med 2007; 204(2): 273-283.
38. - Th1 cells are the source of IL-10-mediated immune suppression in chronic cutaneous leishmaniasis. J Exp Med 2007; 204(2): 285-297.
39. Skapenko A, Niedobitek GU, Kalden JR, Lipsky PE, Schulze-Koops H. Generation and regulation of human Th1-biased immune responses in vivo: a critical role for IL-4 and IL-10. J Immunol 2004; 172: 6427-6434.
40. Cassatella MA, Meda L, Gasperini S, Calzetti F, Bonora S. Interleukin-10 (IL-10) upregulates IL-1 receptor antagonist production from lipopolysaccharide-stimulated human polymorphonuclear leukocytes by delaying mRNA degradation. J Exp Med 1994; 179: 1695-1699.
41. Wong HL, Costa GL, Lotze MT, Wahl SM. Interleukin (IL)-4 differentially regulates monocyte IL-1 family gene expression and synthesis in vitro and in vivo. J Exp Med 1993; 177: 775-781.
42. Essner R, Rhoades K, McBride WH, Morton DL, Economou JS. IL-4 down-regulates IL-1 and TNF gene expression in human monocytes. J Immunol 1989; 142: 3857-3861.
43. Zetser A, Levy-Adam F, Kaplan V, et al. Processing and activation of latent heparanase occurs in lysosomes. J Cell Sci 2004; 117: 2249-2258.
44. Friedmann Y, Vlodavsky I, Aingorn H, et al. Expression of heparanase in normal, dysplastic, and neoplastic human colonic mucosa and stroma: evidence for its role in colonic tumorigenesis. Am J Pathol 2000; 157: 1167-1175.
45. Slavin S, Strober S, Fuks Z, Kaplan HS. Induction of specific tissue transplantation tolerance using fractionated total lymphoid irradiation in adult mice: long-term survival of allogeneic bone marrow and skin grafts. J Exp Med 1977; 146: 34-48.
46. Weiss L, Barak V, Zeira M, et al. Cytokine production in Linomide-treated nod mice and the potential role of a Th (1)/Th(2) shift on autoirmnune and anti-inflammatory processes. Cytokine 2002; 19: 85-93.
47. Hulett MD, Hornby JR, Ohms SJ, et al. Identification of active-site residues of the pro-metastatic endoglycosidase heparanase. Biochemistry 2000; 39: 15659-15667.
48. Goldshmidt O, Zcharia E, Cohen M, et al. Heparanase mediates cell adhesion independent of its enzymatic activity. FASEB J 2003; 17: 1015-1025.
49. Trinchieri G. Interleukin-12 and its role in the generation of Th1 cells. Immunol Today 1993; 14: 335-338.
50. Romagnani S. Type 1 T helper and type 2 T helper cells: functions, regulation and role in protection and disease. Int J Clin Lab Res 1991; 21: 152-158.
51. Leong KG, Karsan A. Signaling pathways mediated by tumor necrosis factor alpha. Histol Histopathol 2000; 15: 1303-1325.
52. Abuzakouk M, Feighery C, Jackson J. Tumour necrosis factor blocking agents: a new therapeutic modality for inflammatory disorders. Br J Biomed Sci 2002; 59: 173-179.
53. Mosmann TR, Cherwinski H, Bond MW, Giedlin MA, Coffman RL. Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. J Immunol 1986; 136: 2348-2357.
54. Romagnani S. Type 1 T helper and type 2 T helper cells: functions, regulation and role in protection and disease. Int J Clin Lab Res 1991; 21(2): 152-158.
55. Sotnikov I, Hershkoviz R, Grabovsky V, et al. Enzymatically quiescent heparanase augments T cell interactions with VCAM-1 and extracellular matrix components under versatile dynamic contexts. J Immunol 2004; 172: 5185-5193.
56. Gingis-Velitski S, Zetser A, Flugelman MY, Vlodavsky I, Ilan N. Heparanase induces endothelial cell migration via protein kinase B/Akt activation. J Biol Chem 2004; 279: 23536-23541.
57. O'Garra A, Vieira P. Regulatory T cells and mechanisms of immune system control. Nat Med 2004; 10: 801-805.
58. Edovitsky E, Lerner I, Zcharia E, Peretz T, Vlodavsky I, Elkin M. Role of endothelial heparanase in delayed-type hypersensitivity. Blood 2006; 107: 3609-3616.